Press Releases

Press Releases

Date Title
January 22, 2019
UNITY Biotechnology Expands Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of the Knee
- Results expected in the second quarter of 2019 - SAN FRANCISCO , Jan. 22, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced further
January 3, 2019
UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye
SAN FRANCISCO , Jan. 03, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected UBX1967 as the lead development